AVINZA™ Will ContributeSignificant Value to our LSPP Portfolio

New sales force in place to target general

pain centers; launched in 2Q with ~80 reps total

True once-daily dosing, unique dual-release formulation, comparatively smooth PK profile

U.S. sustained-release opioid market is $2.3 billion, largest initial market we’ve entered

Negotiating with Elan to co-promote in U.S.

Previous slide

Next slide

Back to first slide

View graphic version